S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Johnson & Johnson

JNJ · Healthcare · · USD
275.23 USD
0.00 (-1.15%)
● Updated 2026-09-07 19:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score STRONG BUY Mid-term (Position)

84
/ 100
Technical 100
Trend & RS 96
Momentum 73
Fundamental 83
Macro 64
Liquidity 53
ComponentScoreWeight
Technical 100.0 20%
Trend & RS 96.4 30%
Momentum 72.9 15%
Fundamental 83.3 10%
Macro 64.4 20%
Liquidity 52.7 5%

Trade Setup

Entry 275.23
Stop Loss 264.21 (4.0%)
Target 1 (1:1) 286.25 (+4.0%)
Target 2 (2:1) 297.27 (+8.0%)
ATR(14) 5.51 (2.0%)
Risk per Share 11.02
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 33.2 -0.67
Momentum 72.9 +0.92
Quality 50.4 +0.02
Composite 52.2

Quality Scores

Piotroski F-Score 6 /9 — Average
✓ ✓ ✗ ✗ ✓ ✗ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 9.29 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 32.0 22.0 +45% above
P/B Ratio 7.8 4.0 Above
Dividend Yield 1.9% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
129.41
vs
Market Price
275.23
Upside
-53.0%
Margin of Safety -112.7%
Stage 1 PV (5yr FCF)77,672,858,719
Terminal Value PV234,183,315,210
Total Enterprise Value311,856,173,929

Assumptions

Base FCF16,599,381,536
Growth Rate (5yr)6.6%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
53.53%
Full Kelly
26.77%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 84/100. Estimated win rate 65%, avg win 10.0%, avg loss 3.3%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

4
Bullish Signals
0
Bearish Signals
61.22
RSI(14)
4.661
MACD

Relative Strength (RS) IMPROVING

90
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+14.1% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High Near 3-month high 27d since high
Sector Outperformance +11.1% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 61.22 NEUTRAL
Macd 4.661 BULLISH
Ma Cross 260.72 / 233.5 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.69x NORMAL

Key Levels

LevelPrice
52-Week High281.07
Bollinger Upper279.63
SMA(200)233.5
SMA(50)260.72
SMA(20)267.55
Current Price275.23
Bollinger Lower255.47
52-Week Low173.33
ATR(14)5.51

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.26x Normal bar — no special VSA pattern
2026-09-01 Normal 0.96x Normal bar — no special VSA pattern
2026-09-02 Normal 1.26x Normal bar — no special VSA pattern
2026-09-03 Normal 0.95x Normal bar — no special VSA pattern
2026-09-04 Normal 0.69x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 272.45 Above Kijun
Kijun-sen (26) 265.14 Base line
Senkou A 268.80 Leading span A
Senkou B 259.32 Leading span B
Cloud 259.32 – 268.80 Bullish (Green)
Price vs Cloud 275.23 Above Cloud
Chikou Span 255.09 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 255.47 – 279.63  |  KC: 259.65 – 275.45

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 9

Anchored VWAP

VWAP: 223.06 Anchor: 2025-09-19 (52w Low) ABOVE AVWAP +23.4%

Heikin-Ashi Trend

BULLISH Full data via /api/advanced/JNJ

Valuation

MetricValue
Market Cap663.28B
P/E (TTM)31.97
Forward P/EN/A
P/B7.80
EPS8.61

Financial Health

MetricValue
Revenue Growth6.6%
Profit Margin21.5%
ROE25.7%
Debt/Equity57.71
Current Ratio1.09
Dividend Yield1.9%
Payout RatioN/A
Beta0.23

Trading Data

275.23
Open
275.23
Day High
275.23
Day Low
3.88M
Volume (0.5x avg)

Recent News (8)

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Zacks · 2026-09-07
Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?
24/7 Wall St. · 2026-09-07
3 Dividend Kings Built to Keep Raising Your Income When Rates Rise
24/7 Wall St. · 2026-09-05
How Much Upside Can BSX Stock's Growth Deliver?
Trefis · 2026-09-04
Was JNJ Stock Rally Actually Its Own?
Trefis · 2026-09-04
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
24/7 Wall St. · 2026-09-04
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
BioPharma Dive · 2026-09-04
Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?
Simply Wall St. · 2026-09-04

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —